{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:28:28Z","timestamp":1776842908764,"version":"3.51.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40261-023-01335-x","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T19:02:27Z","timestamp":1703012547000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis"],"prefix":"10.1007","volume":"44","author":[{"given":"Eg\u00eddio","family":"Freitas","sequence":"first","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Paiva Lopes","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Diogo","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Ana Clara","family":"Valente","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Rosas","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica","family":"Caetano","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Mota","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"5","key":"1335_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40257-021-00613-8","volume":"22","author":"E Freitas","year":"2021","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625\u201338. https:\/\/doi.org\/10.1007\/s40257-021-00613-8.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.20344\/amp.11963","volume":"32","author":"T Torres","year":"2019","unstructured":"Torres T, Ferreira EO, Gon\u00e7alo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606\u201313. https:\/\/doi.org\/10.20344\/amp.11963.","journal-title":"Acta Med Port"},{"issue":"3","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","volume":"23","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Baricitinib: a review in moderate to severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):409\u201320. https:\/\/doi.org\/10.1007\/s40257-022-00684-1.","journal-title":"Am J Clin Dermatol"},{"key":"1335_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18804","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate\u2013severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18804.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1335_CR5","doi-asserted-by":"publisher","first-page":"adv00677","DOI":"10.2340\/actadv.v102.1088","volume":"102","author":"D Rogner","year":"2022","unstructured":"Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022;102:adv00677. https:\/\/doi.org\/10.2340\/actadv.v102.1088.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1346-8138.16350","volume":"49","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, Fujiwara C, Inoue Y, Motegi S. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469\u201371. https:\/\/doi.org\/10.1111\/1346-8138.16350.","journal-title":"J Dermatol"},{"issue":"7","key":"1335_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869\u201379. https:\/\/doi.org\/10.1111\/1346-8138.16763.","journal-title":"J Dermatol"},{"key":"1335_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60:44\u20137. https:\/\/doi.org\/10.2340\/00015555924447.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1080\/09546634.2021.1967268","volume":"33","author":"A Melo","year":"2022","unstructured":"Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment of atopic dermatitis. J Dermatolog Treat. 2022;33(5):2404\u201313. https:\/\/doi.org\/10.1080\/09546634.2021.1967268.","journal-title":"J Dermatolog Treat"},{"issue":"6S","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1097\/DER.0000000000000958","volume":"33","author":"J-J Pereyra-Rodriguez","year":"2022","unstructured":"Pereyra-Rodriguez J-J, Herranz P, Figuras-Nart I, et al. Upadacitinib for the treatment of atopic dermatitis in a spanish cohort\u2014real life: fifty-two\u2013week follow-up results. Dermatitis. 2022;33(6S):S124\u20137. https:\/\/doi.org\/10.1097\/DER.0000000000000958.","journal-title":"Dermatitis"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01335-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:32:41Z","timestamp":1704457961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01335-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"3 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding has been received for the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eg\u00eddio Freitas, MJ. Paiva Lopes, MJ. Cruz, D. Sousa, AC. Valente, L. Teixeira, G. Rosas, M. Caetano, and P. Filipe have no conflicts of interest to declare. Tiago Torres declares the following conflicts of interest: AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, and Sandoz. Bruno Duarte declares the following conflicts of interest: Sanofi, Eli Lilly, Leo Pharma, and Abbvie. Alberto Mota declares the following conflicts of interest: attended advisory boards and or received speaker honorarium for AbbVie, Eli Lilly and Co., LEO Pharma, and Sanofi-Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Disclosures"}},{"value":"EF, MJPL, MJC, DS, ACV, BD, LT, GR, MC, AM, PF, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"According to the National Law for Clinical investigation in Portugal and the institutional guidelines ethics approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received treatment as in good clinical practice, in accordance with Portuguese guidelines. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All included patients had provided written consent for retrospective study of data collected during routine clinical practice","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The data generated during and\/or analyzed for this article are available from the corresponding author on a reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}